|
51.
|
|
17 p, 5.1 MB |
Robust temporal map of human in vitro myelopoiesis using single-cell genomics
/
Alsinet, Clara (Open Targets. Wellcome Genome Campus) ;
Primo, Maria Nascimento (Open Targets. Wellcome Genome Campus) ;
Lorenzi, Valentina (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Bello, Erica (Open Targets. Wellcome Genome Campus) ;
Kelava, Iva (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Jones, Carla P. (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Vilarrasa Blasi, Roser (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Sancho Serra, Carmen (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Knights, Andrew J. (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Park, Jong Eun (Korea Advanced Institute of Science and Technology) ;
Wyspianska, Beata S. (Immunology Research Unit. Medicines Research Centre. GlaxoSmithKline) ;
Trynka, Gosia (Open Targets. Wellcome Genome Campus) ;
Tough, David F. (Immunology Research Unit. Medicines Research Centre. GlaxoSmithKline) ;
Bassett, Andrew (Open Targets. Wellcome Genome Campus) ;
Gaffney, Daniel J. (Wellcome Sanger Institute. Wellcome Genome Campus) ;
Álvarez-Errico, Damiana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vento Tormo, Roser (Wellcome Sanger Institute. Wellcome Genome Campus)
Myeloid cells are central to homeostasis and immunity. Characterising in vitro myelopoiesis protocols is imperative for their use in research, immunotherapies, and understanding human myelopoiesis. Here, we generate a >470K cells molecular map of human induced pluripotent stem cells (iPSC) differentiation into macrophages. [...]
2022 -  10.1038/s41467-022-30557-4
Nature communications, Vol. 13 Núm. 1 (december 2022) , p. 2885
|
|
|
52.
|
|
13 p, 1.2 MB |
Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis
/
Diesch, Jeannine (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Le Pannérer, Marguerite Marie (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Winkler, René (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Casquero, Raquel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Muhar, Matthias (Research Institute of Molecular Pathology (IMP). Vienna BioCenter (VBC)) ;
van der Garde, Mark (German Cancer Consortium (DKTK). Partner Site Munich) ;
Maher, Michael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez Herráez, Carolina (Universitat de Barcelona. Departament de Bioquímica i Fisiologia) ;
Bech-Serra, Joan-Josep (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fellner, Michaela (Research Institute of Molecular Pathology (IMP). Vienna BioCenter (VBC)) ;
Rathert, Philipp (University Stuttgart) ;
Brooks, Nigel (CellCentric. Ltd. Chesterford Research Park) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gentilella, Antonio (Universitat de Barcelona. Departament de Bioquímica i Fisiologia) ;
De La Torre Gómez, Gisela Carolina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zuber, Johannes (Medical University of Vienna. Vienna BioCenter (VBC)) ;
Götze, Katharina S. (Technische Universität München) ;
Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
The nucleotide analogue azacitidine (AZA) is currently the best treatment option for patients with high-risk myelodysplastic syndromes (MDS). However, only half of treated patients respond and of these almost all eventually relapse. [...]
2021 - 10.1038/s41467-021-26258-z
Nature communications, Vol. 12 Núm. 1 (january 2021) , p. 6060
|
|
|
53.
|
|
12 p, 1.9 MB |
Genetic perturbation of PU.1 binding and chromatin looping at neutrophil enhancers associates with autoimmune disease
/
Watt, Stephen (Human Genetics. Wellcome Sanger Institute. Genome Campus) ;
Vasquez, Louella (Human Genetics. Wellcome Sanger Institute. Genome Campus) ;
Walter, Klaudia (Human Genetics. Wellcome Sanger Institute. Genome Campus) ;
Mann, Alice L. (Human Genetics. Wellcome Sanger Institute. Genome Campus) ;
Kundu, Kousik (School of Clinical Medicine. University of Cambridge) ;
Chen, Lu (Sichuan University) ;
Sims, Ying (Human Genetics. Wellcome Sanger Institute. Genome Campus) ;
Ecker, Simone (UCL Cancer Institute) ;
Burden, Frances (National Health Service Blood and Transplant) ;
Farrow, Samantha (National Health Service Blood and Transplant) ;
Farr, Ben (Human Genetics. Wellcome Sanger Institute. Genome Campus) ;
Iotchkova, Valentina (University of Oxford) ;
Elding, Heather (Human Genetics. Wellcome Sanger Institute. Genome Campus) ;
Mead, Daniel (Human Genetics. Wellcome Sanger Institute. Genome Campus) ;
Tardaguila, Manuel (Human Genetics. Wellcome Sanger Institute. Genome Campus) ;
Ponstingl, Hannes (Human Genetics. Wellcome Sanger Institute. Genome Campus) ;
Richardson, David (European Molecular Biology Laboratory. European Bioinformatics Institute) ;
Datta, Avik (European Molecular Biology Laboratory. European Bioinformatics Institute) ;
Flicek, Paul (European Molecular Biology Laboratory. European Bioinformatics Institute) ;
Clarke, Laura (European Molecular Biology Laboratory. European Bioinformatics Institute) ;
Downes, Kate (National Health Service Blood and Transplant) ;
Pastinen, Tomi (Center for Pediatric Genomic Medicine. Children's Mercy) ;
Fraser, Peter (Florida State University) ;
Frontini, Mattia (University of Exeter Medical School) ;
Javierre, B. M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Spivakov, Mikhail (Imperial College Faculty of Medicine) ;
Soranzo, Nicole (University of Cambridge)
Neutrophils play fundamental roles in innate immune response, shape adaptive immunity, and are a potentially causal cell type underpinning genetic associations with immune system traits and diseases. [...]
2021 - 10.1038/s41467-021-22548-8
Nature communications, Vol. 12 Núm. 1 (january 2021) , p. 2298
|
|
|
54.
|
|
|
55.
|
|
14 p, 5.6 MB |
SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade
/
Romero, Octavio A. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vilarrubi, Andrea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Alburquerque-Béjar, Juan Jos (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gómez Moruno, Antonio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Andrades, Álvaro (Universidad de Granada) ;
Trastulli, Deborah (Institut d'Investigació Biomèdica de Bellvitge) ;
Pros, Eva (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Setien, Fernando (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Verdura, Sara (Institut d'Investigació Biomèdica de Bellvitge) ;
Farre, Lourdes (Institut d'Investigació Biomèdica de Bellvitge) ;
Martín-Tejera, Juan F. (Institut d'Investigació Biomèdica de Bellvitge) ;
Llabata, Paula (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Oaknin, Ana (Hospital Universitari Vall d'Hebron) ;
Saigi, María (Institut Català d'Oncologia) ;
Piulats, Josep M. (Institut Català d'Oncologia) ;
Matias-Guiu, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
Medina, Pedro P. (Universidad de Granada) ;
Vidal, August (Parc Científic de Barcelona) ;
Villanueva, Alberto (Parc Científic de Barcelona) ;
Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. [...]
2021 - 10.1038/s41467-021-24618-3
Nature communications, Vol. 12 Núm. 1 (january 2021) , p. 4319
|
|
|
56.
|
|
15 p, 3.2 MB |
p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis
/
Solé Font, Laura (Instituto de Salud Carlos III) ;
Lobo-Jarne, Teresa (Instituto de Salud Carlos III) ;
Álvarez-Villanueva, Daniel (Institut Català d'Oncologia) ;
Alonso-Marañón, Josune (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Guillén, Yolanda (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Guix, Marta (Universitat Pompeu Fabra) ;
Sangrador, Irene (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Rozalén, Catalina (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Vert, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Barbachano, Antonio (Universidad Autónoma de Madrid) ;
Lop Gros, Joan (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Salido, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Bellosillo Paricio, Beatriz (Institut Hospital del Mar d'Investigacions Mèdiques) ;
García-Romero, Raquel (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Garrido, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ;
González Miranda, Jessica (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Martínez-Iniesta, María (Institut Català d'Oncologia) ;
López-Arribillaga, Erika (Group of Biomedical Genomics) ;
Salazar, Ramón. (Institut Català d'Oncologia) ;
Torres, Ferran (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública) ;
Iglesias, Mar (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Celià-Terrassa, Toni (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Munoz, Alberto (Instituto de Salud Carlos III) ;
Villanueva, Alberto (Institut Català d'Oncologia) ;
Bigas Salvans, Anna (Instituto de Salud Carlos III) ;
Espinosa, Lluís (Instituto de Salud Carlos III) ;
Universitat Autònoma de Barcelona
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. [...]
2022 - 10.1038/s41467-022-30382-9
Nature communications, Vol. 13 Núm. 1 (december 2022) , p. 2866
|
|
|
57.
|
|
19 p, 3.3 MB |
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers
/
Shah, Jennifer B. (University of Pennsylvania) ;
Pueschl, Dana (University of Pennsylvania) ;
Wubbenhorst, Bradley (University of Pennsylvania) ;
Fan, Mengyao (University of Pennsylvania) ;
Pluta, John (University of Pennsylvania) ;
D'Andrea, Kurt (University of Pennsylvania) ;
Hubert, Anna P. (University of Pennsylvania) ;
Shilan, Jake S. (University of Pennsylvania) ;
Zhou, Wenting (University of Pennsylvania) ;
Kraya, Adam A. (University of Pennsylvania) ;
Llop Guevara, Alba (Vall d'Hebron Institut d'Oncologia) ;
Ruan, Catherine (University of Pennsylvania. Perelman School of Medicine) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Feldman, Michael (University of Pennsylvania) ;
Morin, Pat J. (University of Pennsylvania) ;
Nayak, Anupma (University of Pennsylvania) ;
Maxwell, Kara N. (University of Pennsylvania) ;
Domchek, Susan M. (University of Pennsylvania) ;
Nathanson, Katherine L. (University of Pennsylvania) ;
Universitat Autònoma de Barcelona
Recurrence is a major cause of death among BRCA1/2 mutation carriers with breast (BrCa) and ovarian cancers (OvCa). Herein we perform multi-omic sequencing on 67 paired primary and recurrent BrCa and OvCa from 27 BRCA1/2 mutation carriers to identify potential recurrence-specific drivers. [...]
2022 - 10.1038/s41467-022-34523-y
Nature communications, Vol. 13 (november 2022)
|
|
|
58.
|
|
14 p, 15.4 MB |
Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy
/
Bertolín Gálvez, Joan (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Sánchez, Víctor (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Ribera Sánchez, Albert (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Jaén Sitges, Maria Luisa (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Garcia, Miquel (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Pujol, Anna (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Sánchez, Xavier (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Muñoz, Sergio (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Marcó, Sara (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Pérez, Jennifer (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Elias, Gemma (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
León, Xavier (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Roca, Carles (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Jimenez, Veronica (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Otaegui Goya, Pedro José (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Mulero, Francisca (Molecular Imaging Unit, Spanish National Cancer Research Center (CNIO)) ;
Navarro Beltrán, Marc (Universitat Autònoma de Barcelona. Departament de Medicina i Cirurgia Animals) ;
Ruberte, Jesús (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals) ;
Bosch i Tubert, Fàtima (Universitat Autònoma de Barcelona. Centre de Biotecnologia Animal i de Teràpia Gènica (CBATEG))
Mucopolysaccharidosis type IVA (MPSIVA) or Morquio A disease, a lysosomal storage disorder, is caused by N -acetylgalactosamine-6-sulfate sulfatase (GALNS) deficiency, resulting in keratan sulfate (KS) and chondroitin-6-sulfate accumulation. [...]
2021 - 10.1038/s41467-021-25697-y
Nature communications, Vol. 12 (september 2021)
|
|
|
59.
|
|
15 p, 1.2 MB |
Energy requirements and carbon emissions for a low-carbon energy transition
/
Slameršak, Aljoša (Universitat Autònoma de Barcelona. Institut de Ciència i Tecnologia Ambientals) ;
Kallis, Giorgos (Universitat Autònoma de Barcelona. Institut de Ciència i Tecnologia Ambientals) ;
O'Neill, Daniel W. (University of Leeds)
Achieving the Paris Agreement will require massive deployment of low-carbon energy. However, constructing, operating, and maintaining a low-carbon energy system will itself require energy, with much of it derived from fossil fuels. [...]
2022 - 10.1038/s41467-022-33976-5
Nature communications, Vol. 13 (2022) , art. 6932
|
|
|
60.
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
